Hoth Therapeutics' HT-001 shows promising interim Phase 2a trial results, improving skin toxicities in cancer patients ...

The rash produces a constant mild generalized sunburn sensation and is more severe during flares. He has sporadic non-specific skin lesions ... The patient has no underlying bacterial, viral ...

The days of a simple cure are long over. We’ve arrived in 2025 — an era where health and wellness are buzzwords, diagnosis ...

Medically reviewed by Jurairat J. Molina, MD Allergic reactions in babies and infants can range from mild to severe or even ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a leading biopharmaceutical company focused on patient-centric solutions, today shared encouraging interim safety and efficacy results from its Phase 2a ...

Live Tinted is a woman-owned business founded by entrepreneur Deepica Mutyala that specializes in clean, vegan, cruelty-free ...

A viral outbreak in China sounds alarmingly familiar to 2019, back in the days before most of us had ever heard of the ...

While Hoth Therapeutics has always been an up-and-comer in the world of biotech, the spotlight is now firmly on them due to the CLEER-001 trial, where early results from the HT-001 treatment are ...

France has reported its first case of the new mpox variant, the country's public health agency announced Tuesday, bringing the total number of EU cases to eight. The individual, located in Brittany, ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR ) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR ), today announced significant progress in ...